ISSN: 1479-6678

Journal Home

Journal Guideline

Future Cardiology Q3 Unclaimed

Taylor and Francis Ltd. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Future Cardiology is a journal indexed in SJR in Molecular Medicine and Cardiology and Cardiovascular Medicine with an H index of 43. It has an SJR impact factor of 0,412 and it has a best quartile of Q3. It has an SJR impact factor of 0,412.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Cardiology and Cardiovascular Medicine (Q3) Molecular Medicine (Q4)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

0,412

SJR Impact factor

43

H Index

85

Total Docs (Last Year)

312

Total Docs (3 years)

2646

Total Refs

422

Total Cites (3 years)

298

Citable Docs (3 years)

1.4

Cites/Doc (2 years)

31.13

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Current molecular pharmacology Q3
Pharmacogenomics and Personalized Medicine Q3
Anti-Cancer Agents in Medicinal Chemistry Q3
Molecular and Cellular Oncology Q3
Viral Immunology Q3

Compare this journals

Aims and Scope

Best articles by citations

Noninvasive techniques to assess myocardial ischemia in hypertensive patients

Rising above the rhetoric: mobile applications and the delivery of cost-effective cardiovascular care in resource-limited settings

Transcatheter valve-in-valve implantation for failing bioprosthetic valves

Prevention and prophylaxis of respiratory syncytial virus in pediatric cardiology: a UK perspective

Superoxide flashes: illuminating new insights into cardiac ischemia and reperfusion injury

WIRION‚Ñ¢ embolic protection system for carotid artery stenting and lower extremity endovascular intervention

Aortic valve disease: preventable or inevitable?

beta-blockers and their mortality benefits: underprescribed in heart failure and chronic obstructive pulmonary disease

Controlling the radiation dose received by patients undergoing cardiac imaging

Challenges in the echocardiographic assessment of aortic stenosis

The glycoprotein IIIa gene polymorphism and the risk of myocardial infarction

Do endurance sports affect female hearts differently to male hearts?

SHOW MORE ARTICLES

A novel method of ventricular closure following transapical access

Transient constrictive pericarditis: an elusive diagnosis

Current and future uses of nesiritide

Vernakalant (RSD1235) in the management of atrial fibrillation: a review of pharmacological properties, clinical efficacy and safety

Update of antibiotic trials for secondary prevention of coronary heart disease

Endogenous carbon monoxide and cardiometabolic risk: can measuring exhaled carbon monoxide be used to refine cardiometabolic risk assessment?

Emerging role of contrast-enhanced MRI in diagnosing vascular malformations

Natriuretic peptide-guided management of patients with heart failure: a decade of progress but still a controversy

Use of implantable cardioverter-defibrillators

Natriuretic peptides and their evolving clinical applications

Use of edoxaban in clinical practice: Comparison of data from the Spanish population in the ETNA-AF-Europe registry

Beating heart continuous coronary perfusion for valve surgery: what next for clinical trials?